Shield Financial Statements From 2010 to 2025
| SHIEF Stock | USD 0.13 0.04 44.28% |
Check Shield Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shield Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Shield financial statements analysis is a perfect complement when working with Shield Therapeutics Valuation or Volatility modules.
Shield |
Shield Therapeutics plc OTC Stock Return On Equity Analysis
Shield Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Shield Therapeutics Return On Equity | -0.57 |
Most of Shield Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shield Therapeutics plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Shield Therapeutics plc has a Return On Equity of -0.5703. This is 97.62% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 83.97% higher than that of the company.
Shield Therapeutics plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shield Therapeutics's current stock value. Our valuation model uses many indicators to compare Shield Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shield Therapeutics competition to find correlations between indicators driving Shield Therapeutics's intrinsic value. More Info.Shield Therapeutics plc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Shield Therapeutics' earnings, one of the primary drivers of an investment's value.About Shield Therapeutics Financial Statements
Shield Therapeutics stakeholders use historical fundamental indicators, such as Shield Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Shield Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Shield Therapeutics' assets and liabilities are reflected in the revenues and expenses on Shield Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Shield Therapeutics plc. Please read more on our technical analysis and fundamental analysis pages.
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company was founded in 2008 and is based in Gateshead, the United Kingdom. SHIELD THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 15 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Shield OTC Stock
Shield Therapeutics financial ratios help investors to determine whether Shield OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shield with respect to the benefits of owning Shield Therapeutics security.